太突然！昔日千亿巨头点名多家券商，称“遭遇谎言与践踏”

Core Viewpoint - The article discusses the backlash from Huaxi Biological against the notion that hyaluronic acid is "outdated," attributing this perspective to a misleading narrative constructed by "restless capital" and certain brokerage reports [1][4]. Group 1: Market Dynamics - Huaxi Biological published an article refuting the "outdated hyaluronic acid" claim, stating that this narrative undermines the efforts of Chinese scientists and the industry [1]. - The rise of the "outdated hyaluronic acid" theory is seen as a tactic to divert attention from the necessary evolution of the industry, pushing capital towards new themes [4]. Group 2: Brokerage Reports - Multiple brokerage reports, including those from Western Securities, were specifically named by Huaxi Biological for spreading misleading comparisons that favor a collagen company over the hyaluronic acid industry [6]. - Huaxi Biological emphasized that these misleading conclusions have been widely disseminated by media and influencers, creating a negative perception that harms the market foundation of a competitive Chinese industry [6]. Group 3: Financial Performance - Huaxi Biological's stock price peaked at 309.43 CNY per share in July 2021 but has since been on a downward trend, closing at 50.60 CNY on May 19, 2023, reflecting a long-term decline [9][12]. - The company reported a significant drop in revenue from its skin science innovation business, which accounted for nearly half of its revenue, with a year-on-year decline of 31.62% [11]. Group 4: Market Position - Huaxi Biological's market capitalization has decreased from over 1,400 billion CNY at its peak to approximately 244 billion CNY currently [12]. - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen their market values rise significantly, with Juzhi Biological nearing 900 billion HKD and Jinbo Biological's stock price doubling recently [15].